| Detailed information |
|---|
| CancerLivER ID | 2231 |
| Biomarker | TP73-AS1 |
| Biomarker Name/Symbol (given in Publication) | TP73-AS1 |
| Biomolecule | LncRNA |
| Subject | Human |
| Degree of Validity | Differentially expressed between HCC and normal; High TP73-AS1 expression was correlated with worse clinicopathological features, poorer prognosis and shorter ;survival; but not validated on independent patient cohort |
| Experimental Condition | HCC v/s Normal; associated with worse clinicopathological features, poorer prognosis and shorter survival |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC (with more than 2 fold change) |
| Level of significance | p < 0.001 |
| Source | Tissue |
| PMID | 28403886 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | NA |
| Cohort | The human HCC cells, HCCLM3, MHCC97L, SMMC7722, Hep3B and HepG2, and normal hepatocyte THLE-3; 84 paired HCC specimens and corresponding adjacent non-tumor tissues |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |